Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Genentech, Inc.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: June 16, 2011
Last updated: January 14, 2016
Last verified: January 2016